Jacob Johnson
Stock Analyst at Stephens & Co.
(3.67)
# 722
Out of 4,854 analysts
77
Total ratings
47.46%
Success rate
8.49%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $243.58 | -1.47% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.69 | -10.25% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $6.75 | -11.11% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $28.29 | +112.09% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $192.15 | +63.93% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $398.36 | +70.70% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $126.68 | +34.20% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $5.78 | -13.49% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $2.15 | +411.63% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $23.24 | +63.51% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $6.65 | +155.83% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.38 | +81.16% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $48.31 | +80.09% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $218.58 | +78.42% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $7.13 | +152.45% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $2.26 | +165.49% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $21.50 | +34.88% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $104.18 | +24.78% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $141.20 | +167.00% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $243.58
Upside: -1.47%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.69
Upside: -10.25%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $6.75
Upside: -11.11%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $28.29
Upside: +112.09%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $192.15
Upside: +63.93%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $398.36
Upside: +70.70%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $126.68
Upside: +34.20%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $5.78
Upside: -13.49%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.15
Upside: +411.63%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $23.24
Upside: +63.51%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $6.65
Upside: +155.83%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.38
Upside: +81.16%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $48.31
Upside: +80.09%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $218.58
Upside: +78.42%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $7.13
Upside: +152.45%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $2.26
Upside: +165.49%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $21.50
Upside: +34.88%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $104.18
Upside: +24.78%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $141.20
Upside: +167.00%